<DOC>
	<DOCNO>NCT00619359</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , efficacy MK0517 prevent Chemotherapy-Induced Nausea Vomiting ( CINV ) associate Cisplatin chemotherapy .</brief_summary>
	<brief_title>Evaluation Fosaprepitant ( MK0517 ) Single Dose Schedule ( 0517-017 )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient male female least 18 year age ; schedule receive first course cisplatin chemotherapy dose 70 mg/m2 high ; predict life expectancy 3 month great Patient post menopausal , premenopausal , must use doublebarrier contraception Patient symptomatic primary metastatic CNS malignancy Patient receive receive Radiation therapy abdomen pelvis week prior Treatment Day 1 though Day 6 Patient vomit 24 hour prior treatment Day 1 Patient active infection ; Patient use illicit drug current evidence alcohol abuse Patient pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>